BNP/CALL/NOVO-NORDISK B/750/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 10:21:02 2024-07-04 EDT | ||
| 3.06 EUR | -0.97% |
|
| Current month | -14.17% | ||
| 1 month | +20.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 3.06 | -0.97% |
| 24-07-03 | 3.09 | -2.52% |
| 24-07-02 | 3.17 | -8.12% |
| 24-07-01 | 3.45 | -4.17% |
| 24-06-28 | 3.6 | +2.86% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 10:21 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC1F3P |
| ISIN | DE000PC1F3P4 |
| Date issued | 2023-12-08 |
| Strike | 750 kr |
| Maturity | 2024-09-20 (78 Days) |
| Parity | 10 : 1 |
| Emission price | 0.75 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.78 € |
|---|---|
| Lowest since issue | 0.61 € |
| Spread | 0.04 € |
| Spread % | 1.28% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
